Vaccination for Pancreatic Ductal Adenocarcinoma: A Hard Nut to Crack
Salas-Benito D (1,2), Melero I (2,3,4), Ponz-Sarvise M (5,4,6).
(1) Department of Medical Oncology, Clinica Universidad de Navarra, Pamplona, Spain.
(2) Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
(3) Department of Immunology and Immunotherapy, Clinica Universidad de Navarra, Pamplona, Spain.
(4) IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
(5) Department of Medical Oncology, Clinica Universidad de Navarra, Pamplona, Spain.
(6) Program in Solid Tumors and Biomarkers, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
Magazine: Clinical Cancer Research
Date: Sep 15, 2019Immunology [SP] Medical Oncology
No immunotherapy strategy is yet offering consistent results against pancreatic ductal adenocarcinoma. A randomized clinical trial testing repeated immunization with a Listeria monocytogenes-based vaccine encoding for mesothelin in combination with a GM-CSF-transfected allogeneic pancreatic cell vaccine reports no survival benefit for the vaccinated patients.See related article by Le et al., p. 5493.
CITATION Clin Cancer Res. 2019 Sep 15;25(18):5435-5437. doi: 10.1158/1078-0432.CCR-19-1753. Epub 2019 Jul 17
you maybe interested
The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.
The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.
Learn why we are different from other healthcare centers. Quality, speed, comfort and results.